drugset / Trial / NCT06056830
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NaSingle-groupOpen-labelDiagnostic
Summary
The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.
Timeline
- Start
- 2023-12-21
- Primary completion
- 2026-09
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 64Cu-SAR-bisPSMA | Diagnostic / imaging agent | 200 mbq | Other |